Details of the Drug Combinations

General Information of This Drug (ID: DMR21Q3)

Drug Name

Clevudine DMR21Q3

Synonyms

Clevudine; 163252-36-6; Levovir; L-FMAU; UNII-IN51MVP5F1; Clevudine (Levovir); IN51MVP5F1; 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)thymine; 1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; AK106264; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; Clevudine [USAN:INN]; Revovir; Clevudine (USAN)

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis B	1E51	Phase 4	[1]
Hepatitis B virus infection	1E51.0	Phase 3	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Clevudine + Adefovir	DCA9F13	Adefovir	Chronic Hepatitis B	[4]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00501124) Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV. U.S. National Institutes of Health.
2	2011 Pipeline of Bukwang.
3	ClinicalTrials.gov (NCT04347915) The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT00798460) Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients